Skip to main
DHR
DHR logo

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Danaher Corporation has demonstrated significant growth prospects, with performance obligations increasing to $4.9 billion in Q2 2025, up from $4.5 billion in Q1 2025, indicating strong demand for its products. The company is projected to experience a 4.5% growth ramp in its Life Sciences segment during Q4 2025, driven by favorable comparisons in Genomics and contributions from new product launches, alongside an improving performance in China. Additionally, the Cepheid Respiratory business is expected to generate substantial revenue, with forecasts suggesting $300-350 million in Q3 2025 and $450-500 million in Q4 2025, reflecting a strong positioning in the diagnostic market.

Bears say

Danaher's financial outlook exhibits a concerning trend as the percentage of obligations expected to be recognized as revenue within the next 12 months has decreased from 48% to 46%, indicating a potential slowdown in revenue generation. Additionally, the company faces substantial risks associated with geopolitical disruptions, foreign exchange fluctuations, and the uncertainty of recovery in high-growth end-markets, notably in China. Despite some confidence regarding biotechnology and life sciences revenue, the overall guidance has come in slightly below expectations for 3Q25, suggesting that growth may not proceed as favorably as anticipated.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $248.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $248.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.